Phase 2 N=10 Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
Kidney Transplantation · Kidney Disease
Primary: Number of Acute Rejections in All Enrolled Participants — 1 Rejection Events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients
Liver Transplant · Liver Transplantation
Primary: Proportion of Participants Successfully Withdrawn From Immunosuppression — 0.60 Proportion of participants
Phase 2 N=12 Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
Phase 3 N=36 The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
Antibody-mediated Rejection · Hyperacute Rejection of Cardiac Transplant · Left Ventricular Dysfunction
Primary: Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction — 4 Participants
Phase 2 N=31 Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
Phase 2 N=40 Belatacept Post Depletional Repopulation to Facilitate Tolerance
Organ Transplantation
Primary: Number of Patients Successfully Withdrawn From Oral Immunosuppression — 12; 7 Participants
Phase 2 N=20 Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection
Kidney Transplantation
Primary: Post-transplant Biopsy to Identify Rejection Episodes — 2; 3 Episode of rejection
Phase 2 N=9 Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
Kidney Transplantation · Kidney Disease · Kidney Failure
Primary: Overall Participant Survival at One Year Post Kidney Transplant — 4; 5 participants
N/A N=40 Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
End Stage Renal Failure With Renal Transplant
Primary: Change in T Cell & B Cell Generation — 1.05; 0.93; 0.8; 1.12 Mean % of Treg cells in peripheral blood
Phase 4 N=222 Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
Graft Rejection
Primary: Patient Survival — 109; 104 Participants
N/A N=30 Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
Liver Transplantation
Primary: Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery — 72; 87.8; 51.0 mL/min
Phase 2 N=25 A Study of Belimumab in the Prevention of Kidney Transplant Rejection
Transplantation, Organ
Primary: Change From Baseline in naïve B Cells From Baseline to Week 24 — 4.0; -30.4 cells/mm^3
Phase 4 N=150 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients
Immunosuppression
Primary: Mean International Society for Heart and Lung Transplantation Biopsy Score Over the First 6 Months Post-transplantation — 0.7; 0.65 units on a scale
Phase 2 N=130 Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation
Kidney Diseases · Kidney Transplantation · Kidney Transplant
Primary: The Difference in Linear Growth by Treatment Assignment at 1 Year Post Kidney Transplantation — 0.37; 0.35 Standard Deviation Score (SDS) — p=0.79
Phase 2 N=5 Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys
Graft Rejection · Kidney Disease
Primary: Number of Patients With Renal Allograft Rejection — 5 participant
Phase 2 N=27 Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
Liver Disease · Liver Transplantation
Primary: Proportion of Participants Who Have Graft Loss or Death — 0.22 Proportion of Participants
Phase 4 N=6 Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
Nephrotoxicity
Primary: Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) — 2.25 ml/min/1.73m2
Phase 2 N=5 Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Kidney Transplantation · Kidney Failure, Chronic
Primary: Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks — 3 participants
N/A N=70 A Study of mDOT for Immunosuppressant Adherence in Solid Organ Transplant Recipients
Medication Adherence · Liver Transplantation · Kidney Transplantation
Primary: Medication Adherence Via Medication Level Variability Index (MLVI) — 23; 24; 10; 8 Participants
N/A N=15 The Effect of Rituximab on the Development of Anti-Donor Antibodies
Renal Transplant Rejection
Primary: Change in Biopsy Cell Densities From Baseline to Follow-up — -164; -122.5; -129.4; 30.4 cells/mm^3 — p=0.25
Phase 4 N=105 Steroid Withdrawal and Donor-specific Anti-HLA Antibodies in Renal Transplant Patients
Other Complication of Kidney Transplant · Renal Transplant Rejection
Primary: Cases of Kidney Transplant Patients With DSA — 0; 0 Participants
N/A N=21 Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance
Renal Transplant Rejection
Primary: Radiologically Detectable Differences in Signal Intensity Between Healthy and Rejected Kidneys, Measured Using T2* Maps — 31.1; 23.3 ms (delayed postcontrast scans)
Phase 2 N=275 Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
Hepatitis C · Hepatitis C, Chronic · Nonimmune Nonviral Causes of Liver Failure
Primary: Number of Participants With Clinical Complications Usually Attributed to Immunosuppression — 12; 4 participants
Phase 2 N=58 Regimen Optimization Study
Kidney Transplantation
Primary: Percentage of Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6 Months — 7.7; 9.4 Percentage of participants
Phase 3 N=223 EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
Chronic Obstructive Pulmonary · Idiopathic Pulmonary Fibrosis · Cystic Fibrosis
Primary: Number of Participants With the Event Death, Graft Loss, Acute Rejection and/or Loss to Follow-up (Whichever Occurred First) — 33; 29; 30 participants
Phase 4 N=29 Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Kidney Transplant · Diabetes Mellitus, Type 2 · Diabetic Nephropathy
Primary: Freedom From Insulin Therapy Post Transplant — 3; 4 Participants
Phase 4 N=180 Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
End-stage Renal Disease
Primary: Chronic Allograft Nephropathy (Cumulative Calcineurin-inhibitor Nephrotoxicity/Transplant Nephropathy) Per Protocol Surveillance Kidney Biopsies (Banff Grading…
Phase 4 N=434 A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation
Heart Transplantation
Primary: Number of Participants Who Developed Acute Rejection Episode Within 6 Months Post-Transplant — 77; 104 participants — p=0.007
Phase 1 N=2 Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
Kidney Failure, Chronic · Renal Insufficiency
Primary: Number of Participants With Successful Withdrawal of Immunosuppression — 2 Participants
Phase 4 N=40 Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients
Kidney Transplantation
Primary: Incidence of Acute Rejection (Banff '97) or Antibody Mediated Rejection — 2; 0; 5; 3 participants